Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of drug targeting (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10611869608996830PMID 8866658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Liposomes: preparation, characterization, and preservation.

  2006cited by this paper
• Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.

  1995cited by this paper
• Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

  1995cited by this paper
• Liposomal-entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma.

  1995cited by this paper
• Liposomal anthracyclines.

  1994cited by this paper
• Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft.

  1994cited by this paper
• Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes.

  1993cited by this paper
• Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs

  1993cited by this paper
• Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

  1993cited by this paper
• Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases.

  1993cited by this paper
• Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes

  1992cited by this paper
• Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.

  1992cited by this paper
• Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice.

  1992cited by this paper
• Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors.

  1992cited by this paper
• Pharmacokinetics and antitumor activity of epirubicin encapsulated in long‐circulating liposomes incorporating a polyethylene glycol‐derivatized phospholipid

  1992cited by this paper
• Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.

  1992cited by this paper
• Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

  1991cited by this paper
• Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times.

  1991cited by this paper
• Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies.

  1990cited by this paper
• Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

  1989cited by this paper
• Liposomes: preparation, characterization, and preservation.

  1988cited by this paper
• Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

  1988cited by this paper
• Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential.

  1985cited by this paper
• The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation.

  1985cited by this paper
• Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

  1982cited by this paper
• Enhancement of growth of a radiation-induced lymphoma by T cells from normal mice.

  1980cited by this paper
• Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents.

  1977cited by this paper
• Characterization and responsiveness of the Madison 109 lung carcinoma to various antitumor agents.

  1977cited by this paper

• Immune Implications of Cholesterol-Containing Lipid Nanoparticles

  2024cites this paper
• Looking Back, Moving Forward: Lipid Nanoparticles as a Promising Frontier in Gene Delivery

  2023cites this paper
• The Transformative Potential of Lipid Nanoparticle–Protein Corona for Next-Generation Vaccines and Therapeutics

  2023cites this paper
• Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges.

  2022cites this paper
• Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting

  2022cites this paper
• PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery

  2022cites this paper
• Membrane Fusion Models for Bioapplications

  2021cites this paper
• Clinical Application of Cytokines in Cancer Immunotherapy

  2021cites this paper
• DDDT_A_308578 2269..2287

  2021cites this paper
• Physicochemical characterization, toxicity and in vivo biodistribution studies of a discoidal, lipid-based drug delivery vehicle: Lipodisq nanoparticles containing doxorubicin

  2020cites this paper
• Biological response and cytotoxicity induced by lipid nanocapsules

  2020cites this paper
• Suppression of cancer stem cells

  2020cites this paper
• Exposure of liposomes containing nanocrystallised ciprofloxacin to digestive media induces solid-state transformation and altered in vitro drug release.

  2020cites this paper
• Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

  2020cites this paper
• Understanding liposomal drug nanocrystal formulations and their potential in oral drug delivery

  2019cites this paper
• Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin

  2019cites this paper
• Novel analytical methods to assess the chemical and physical properties of liposomes.

  2018cites this paper
• Solid State Characterization of Ciprofloxacin Liposome Nanocrystals.

  2018cites this paper
• Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide

  2017cites this paper
• Synergistic retention strategy of RGD active targeting and radiofrequency-enhanced permeability for intensified RF & chemotherapy synergistic tumor treatment.

  2016cites this paper
• Nanoparticulate Drug Delivery Systems

  2016cites this paper
• New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

  2016cites this paper
• Reduction-responsive dithiomaleimide-based nanomedicine with high drug loading and FRET-indicated drug release.

  2015cites this paper
• Effects of cholesterol incorporation on the physicochemical, colloidal, and biological characteristics of pH-sensitive AB₂ miktoarm polymer-based polymersomes.

  2014cites this paper
• Biphasic magnetic nanoparticles-nanovesicle hybrids for chemotherapy and self-controlled hyperthermia.

  2014cites this paper
• American Cancer Society (ACS)

  2014cites this paper
• Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.

  2013cites this paper
• BIOTECNOLOGIA DE SISTEMAS COLOIDAIS APLICÁVEL NA OTIMIZAÇÃO DO EFEITO TERAPÊUTICO DE FÁRMACOS USADOS NO TRATAMENTO DO CÂNCER

  2013cites this paper
• Polyethylene Glycol-Coated (Pegylated) Liposomal Doxorubicin

  2012cites this paper
• Challenges in Development of Targeted Liposomal Therapeutics

  2012cites this paper
• Polyethylene Glycol-Liposomal Doxorubicin

  2012cites this paper
• Anticancer drugs in liposomal nanodevices: a target delivery for a targeted therapy.

  2012cites this paper
• Liposomal alendronate for the treatment of restenosis.

  2012cites this paper
• Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy

  2011cites this paper
• Remote-loading labeling of liposomes with 99mTc-BMEDA and its stability evaluation: effects of lipid formulation and pH/chemical gradient

  2011cites this paper
• Application of Magnetic Nanoparticles to Gene Delivery

  2011cites this paper
• Clinical development of nano-dds

  2011cites this paper
• KOHDENNETUT LIPOSOMIT SYÖVÄN HOIDOSSA

  2010cites this paper
• Cancer Chemotherapy by DDS

  2010cites this paper
• Amino Acid Coupled Liposomes for the Effective Management of Parkinsonism

  2009cites this paper
• Peptide- and aptamer-functionalized nanovectors for targeted delivery of therapeutics.

  2009cites this paper
• In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells.

  2009cites this paper
• Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

  2009cites this paper
• Engineered nanocarriers of doxorubicin: a current update.

  2008cites this paper
• Designing PEGylated therapeutic molecules: advantages in ADMET properties

  2008cites this paper
• Drug carrier systems for anticancer agents: A review

  2008cites this paper
• Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.

  2008cites this paper
• The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.

  2008cites this paper
• Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

  2008cites this paper
• The effect of magnetic targeting on the uptake of magnetic-fluid-loaded liposomes by human prostatic adenocarcinoma cells.

  2008cites this paper
• The in vitro kinetics of the interactions between PEG-ylated magnetic-fluid-loaded liposomes and macrophages.

  2007cites this paper
• Nano-Carriers of Drugs and Genes for the Treatment of Restenosis

  2007cites this paper
• Local and average gloss from flat-faced sodium chloride tablets.

  2006cites this paper
• NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

  2006influential citation
• Reduced Toxicity and Superior Therapeutic Activity of a Mitomycin C Lipid-Based Prodrug Incorporated in Pegylated Liposomes

  2006cites this paper
• Pharmacokinetic Consequences of Pegylation

  2006influential citation
• A tumor vasculature targeted liposome delivery system for combretastatin A4: Design, characterization, and in vitro evaluation

  2006cites this paper
• Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats

  2005cites this paper
• Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin

  2005cites this paper
• Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes

  2005cites this paper
• Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.

  2005cites this paper
• Liposomal Drug Delivery Systems for Cancer Therapy

  2004cites this paper
• Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4.

  2004cites this paper
• Clinical trial of MCC-465, a doxorubicin encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer

  2004cites this paper
• Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer.

  2004cites this paper
• Development of ligand-targeted liposomes for cancer therapy

  2004cites this paper
• がん治療におけるDrug Delivery System

  2003cites this paper
• An interim analysis of phase I clinical trial of MCC-465, a doxorubicin (DXR) encapsulated in PEG-immunoliposome, in patients with metastatic stomach cancer.

  2003cites this paper
• Pharmacokinetics of Pegylated Liposomal Doxorubicin

  2003cites this paper
• Polyethylene glycol-liposomal doxorubicin: a review of its use in the management of solid and haematological malignancies and AIDS-related Kaposi's sarcoma.

  2002cites this paper
• Steric stabilization of liposomes — a review

  2002cites this paper
• Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models

  2002cites this paper
• Development of novel topical tranexamic acid liposome formulations.

  2002cites this paper
• Advances in the therapy of high-grade glioma at relapse: pegylated liposomal doxorubicin

  2002cites this paper
• Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil)

  2002cites this paper
• Long‐term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

  2001cites this paper
• Conventional and gemini surfactants embedded within bilayer membranes: contrasting behavior.

  2001cites this paper
• Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy

  2001cites this paper
• Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.

  2001cites this paper
• Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826).

  2000cites this paper
• Tissue dosimetry of liposome-radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals.

  2000cites this paper
• Current status of pH-sensitive liposomes in drug delivery.

  2000cites this paper
• An overview on the use of TNF-alpha: our experience with regional administration and developments towards new opportunities for systemic application.

  2000cites this paper
• Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.

  2000cites this paper
• Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

  1999influential citation
• In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.

  1999cites this paper
• Applications of liposome technology in modulating p-glycoprotein mediated multidrug resistance

  1999cites this paper
• Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.

  1999cites this paper
• Liposome-Mediated Delivery of Radionuclides to Tumor Models for Cancer Radiotherapy: A Quantitative Analysis

  1999cites this paper
• Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?

  1999cites this paper
• The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs.

  1999cites this paper
• Control of tumour vascular permeability.

  1998cites this paper
• The biodistribution of novel 200-nm palmitoyl muramic acid vesicles

  1998cites this paper
• Low-molecular-weight heparin-conjugated liposomes with improved stability and hemocompatibility.

  1998cites this paper
• A simple and efficient method for radiolabeling of preformed liposomes.

  1998cites this paper
• Effects of PEG-lipids on permeability of phosphatidylcholine/cholesterol liposomes in buffer and in human serum.

  1998cites this paper
• Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model.

  1998cites this paper
• Chapter 4.3 - Pharmacologic advantages of anthracyclines encapsulated in poly-ethylene-glycol coated stealth liposomes: Potential for tumor targeting

  1998cites this paper
• Stealth™ Liposomes as Carriers of Doxorubicin

  1998cites this paper
• Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.

  1997cites this paper